Real-world comparative effectiveness of first-line abemaciclib versus palbociclib in HR+/HER2- metastatic breast cancer: A propensity-matched retrospective analysis
In this large, real-world cohort study, first-line abemaciclib was associated with a significant overall survival benefit compared to palbociclib for patients with HR+/HER2-mBC. This finding was robust across multiple sensitivity analyses. These results provide valuable evidence to inform treatment decisions in the absence of direct randomized trial data.
Authors
- Wei-Cheng Chang (ORCID: https://orcid.org/0000-0002-8937-6105)
- Po‐Huang Chen (ORCID: https://orcid.org/0000-0002-0280-6417)
- Hsin‐Yu Chen (ORCID: https://orcid.org/0000-0002-2765-1685)
- Cho‐Hao Lee (ORCID: https://orcid.org/0000-0002-6061-5168)
- Li‐Ting Kao (ORCID: https://orcid.org/0000-0003-0692-7408)
- Hong‐Jie Jhou (ORCID: https://orcid.org/0000-0003-3304-4643)
- Tina Yi Jin Hsieh (ORCID: https://orcid.org/0000-0001-6296-0689)
- Ming‐Shen Dai (ORCID: https://orcid.org/0000-0002-3953-5243)
Institutions
- Ministry of Health and Welfare (KR)
- Beth Israel Deaconess Medical Center (US)
- Chi Mei Medical Center (TW)
- Changhua Christian Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- The Breast
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1016/j.breast.2025.104597
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tri-Service General Hospital